Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression

American Journal of Translational Research

Volumn 2, Issue 1, 2010, Pages 88-94

  Yang, Kui ^a   Tang, Yaqiong ^a   Iczkowski, Kenneth A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Alternate splicing; CD44; Fibronectin; Hyaluronan; Hydantoin; Phenyl methylene hydantoin; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BETA1 INTEGRIN; FIBRONECTIN; FIBRONECTIN RECEPTOR; HERMES ANTIGEN; HYALURONIC ACID; HYDANTOIN DERIVATIVE; PHENYLMETHYLENE HYDANTOIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL STRAIN BPH 1; CELL STRAIN PC 3M; CONTROLLED STUDY; HUMAN; HUMAN CELL; LABELING INDEX; MALE; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 77953398669     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Iczkowski KA, Pantazis CG Collins, J. The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol 1997;6:119-129.
2. Iczkowski KA, Bai S Pantazis, CG. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 2003;23: 3129-3140.
3. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA. Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004;84:894-907.
4. Iczkowski KA, Omara-Opyene AL Shah GV. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. Anticancer Res 2006;26:2863-2872.
5. Vis AN, van Rhijn BW, Noordzij MA, Schröder FH, van der Kwast TH. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002;197:148-154.
6. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH, van der Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000;164:2156-2161.
7. Harrison GM, Davies G, Martin TA, Mason MD, Jiang WG. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol Rep 2006;15:199-206.
8. Mudit M, Khanfar M, Muralidharan A, Thomas S, Shah GV, van Soest RW, El Sayed KA. Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products. Bioorg Med Chem 2009;17:1731-1738.
9. Shah GV, Muralidharan A, Thomas S, Gokulgandhi M, Mudit M, Khanfar M, El Sayed K. Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis. Mol Cancer Ther 2009;8:509-520.
10. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S. Introduction of antisense CD44s cDNA downregulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001;91:67-75.
11. Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV. Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res 2005;25:2075-2083.
12. Livak KL, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCT) method. Methods 2001;25:402-408.
13. Miyake H, Hara I, Okamoto I, Gohji K, Yamanaka K, Arakawa S, Saya H, Kamidono S. Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. J Urol 1998;160:1562-1566.
14. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate. 2009;69:787-798.
15. Buess M, Rajski M, Vogel-Durrer BML, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44+/CD24- phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009;11:987-1002.
16. Gao AC, Lou W, Sleeman JP, Isaacs JT. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 1998;58:2350-2352.
17. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001;15:968-980.
18. Bai Y, Liu Y, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressive activity of merlin. Oncogene 2007;26:836-850.
19. Horiguchi A, Zheng R, Shen R, Nanus DM. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate 2008;68:975-994.
20. Basappa, Ananda Kumar CS, Nanjunda Swamy S, Sugahara K, Rangappa KS. Anti-tumor and anti-angiogenic activity of novel hydantoin derivatives: Inhibition of VEGF secretion in liver metastatic osteosarcoma cells. Bioorg Med Chem 2009;17:4928-4934.